A microbiota-targeted strategy to attenuate antipsychotic-induced weight gain

Simple item page
dc.contributor.advisorSchellekens, Harriet
dc.contributor.advisorEnglish, Jane
dc.contributor.authorLipuma, Timothyen
dc.date.accessioned2023-09-20T09:14:20Z
dc.date.available2023-09-20T09:14:20Z
dc.date.issued2023en
dc.date.submitted2023
dc.description.abstractBackground: Atypical antipsychotics such as olanzapine are an essential treatment for psychotic-spectrum disorders, but their use is associated with significant weight gain and increased cardiometabolic disease risk. Attenuating these side effects could improve the tolerability and adherence to antipsychotic medications. Evidence suggests that the microbiome plays a role in antipsychotic-induced weight gain, thus targeting the microbiome may be a viable therapeutic strategy to attenuate the side effect profile of antipsychotics like olanzapine. Furthermore, metabolomics approaches are being increasingly employed to elucidate disease pathophysiology and potential therapeutic targets, but these strategies have not yet been applied to the problem of antipsychotic-induced obesity and hyperphagia. Aims: The primary aims of this study are to (1) investigate if combined microbiome-targeted treatments (probiotic [APC1472], prebiotic [xanthohumol], and their combination) with olanzapine attenuate antipsychotic-induced obesity, metabolic dysfunction, and hyperphagia in female Sprague-Dawley rats, and (2) analyse blood plasma using discovery metabolomics to generate potential mechanistic and therapeutic targets related to the side effects of olanzapine. Methods: Animals were treated with olanzapine (2 mg/kg body weight) alone (n=12), olanzapine with probiotic (n=11), olanzapine with prebiotic (n=11), olanzapine with probiotic and prebiotic (n=12) or control vehicle (n=12) twice a day via intraperitoneal injection for 31 days. Changes in body weight, adiposity, glucose metabolism, dietary intake, anxiety-like behaviour, plasma biomarkers (corticosterone, insulin, ghrelin), and hypothalamic and hepatic gene expression were examined. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) and subsequent metabolomic analysis using Progensis QI and Metaboanalyst were used to characterise plasma differences between the olanzapine treatment group and controls. Results: After the study conclusion, quality control issues with the probiotic formulation were discovered, limiting the interpretability of the data from those treatment groups. However, the olanzapine treatment displayed increased weight gain, dietary intake, and hypothalamic genes related to ghrelinergic signalling. Olanzapine did not increase adiposity, change hepatic gene expression, plasma biomarkers, or hypothalamic genes related to anorexigenic signalling. No treatments attenuated olanzapine-induced weight gain. There were no observed differences in anxiety-like behaviour between any groups. Lastly, the metabolomics investigation revealed several highly differentially expressed metabolites; two androstanoids and one endocannabinoid (oleamide). Conclusion: These findings indicate that olanzapine-associated increases in hypothalamic ghrelinergic signalling can occur before or without the onset of peripheral changes in metabolic health. Although the attenuation of olanzapine-associated increases in hypothalamic ghrelinergic signalling could not be assessed due to the quality control issues with the probiotic, targeting ghrelinergic signalling via microbiome-targeted approaches warrants further research. Additionally, the metabolomics analyses highlight oleamide as a novel metabolite that is potentially at the intersection of the endocannabinoid system, the microbiota, and olanzapine treatment, but further research is needed to clarify if the observed increase in oleamide is due to changes in host and/or microbial metabolism.en
dc.description.statusNot peer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationLipuma, T. C. 2023. A microbiota-targeted strategy to attenuate antipsychotic-induced weight gain. MSc Thesis, University College Cork.
dc.identifier.endpage100
dc.identifier.urihttps://hdl.handle.net/10468/15009
dc.language.isoenen
dc.publisherUniversity College Corken
dc.rights© 2023, Timothy Cody Lipuma.
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/
dc.subjectOlanzapine
dc.subjectMetabolomics
dc.subjectMicrobiome
dc.subjectIn vivo
dc.subjectHypothalamus
dc.subjectObesity
dc.titleA microbiota-targeted strategy to attenuate antipsychotic-induced weight gain
dc.typeMasters thesis (Research)en
dc.type.qualificationlevelMastersen
dc.type.qualificationnameMSc - Master of Scienceen
Files
Original bundle
Now showing 1 - 3 of 3
Thumbnail Image
Name:
LipumaT_MSc2023.docx
Size:
3.31 MB
Format:
Microsoft Word XML
Description:
Full Text E-thesis (Word)
Thumbnail Image
Name:
LipumaT_MSc2023.pdf
Size:
4.02 MB
Format:
Adobe Portable Document Format
Description:
Full Text E-thesis
Download
Thumbnail Image
Name:
Submission for Examination Form
Size:
375.23 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
5.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Theses
Anatomy and Neuroscience - Masters by Research Theses
College of Science, Engineering and Food Science - Masters by Research Theses